US 11,814,435 B2
Therapeutic antibodies and their uses
Tracy Chia-Chien Kuo, San Mateo, CA (US); Javier Fernando Chaparro Riggers, San Mateo, CA (US); Wei Chen, Cupertino, CA (US); Amy Shaw-Ru Chen, San Jose, CA (US); Edward Derrick Pascua, Oakland, CA (US); Thomas John Van Blarcom, Oakland, CA (US); Leila Marie Boustany, Redwood City, CA (US); Weihsien Ho, Belmont, CA (US); Yik Andy Yeung, South San Francisco, CA (US); Pavel Strop, San Mateo, CA (US); and Arvind Rajpal, San Francisco, CA (US)
Assigned to PFIZER INC., New York, NY (US)
Filed by PFIZER INC., New York, NY (US)
Filed on Aug. 27, 2020, as Appl. No. 17/005,073.
Application 17/005,073 is a division of application No. 16/017,974, filed on Jun. 25, 2018, granted, now 10,793,635.
Application 16/017,974 is a division of application No. 15/878,344, filed on Jan. 23, 2018, granted, now 10,040,860, issued on Aug. 7, 2018.
Application 15/878,344 is a division of application No. 15/085,644, filed on Mar. 30, 2016, granted, now 9,969,809, issued on May 15, 2018.
Claims priority of provisional application 62/301,582, filed on Feb. 29, 2016.
Claims priority of provisional application 62/146,504, filed on Apr. 13, 2015.
Claims priority of provisional application 62/146,843, filed on Apr. 13, 2015.
Prior Publication US 2021/0054087 A1, Feb. 25, 2021
Int. Cl. C07K 16/00 (2006.01); C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 31/454 (2006.01); A61K 31/704 (2006.01); A61K 31/69 (2006.01); A61K 47/68 (2017.01); A61K 39/00 (2006.01)
CPC C07K 16/2878 (2013.01) [A61K 31/454 (2013.01); A61K 31/69 (2013.01); A61K 31/704 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 47/6801 (2017.08); A61K 47/6849 (2017.08); C07K 16/2803 (2013.01); C07K 16/2809 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/92 (2013.01)] 7 Claims
 
1. An isolated antibody that specifically binds to CD3, wherein the antibody comprises:
(a) a VH CDR1 comprising the amino acid sequence shown in SEQ ID NO: 332, a VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 417, a VH CDR3 comprising the amino acid sequence shown in SEQ ID NO: 335, a VL CDR1 comprising the amino acid sequence shown in SEQ ID NO: 340, a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 341, and a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 342;
(b) a VH CDR1 comprising the amino acid sequence shown in SEQ ID NO: 407, a VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 411, a VH CDR3 comprising the amino acid sequence shown in SEQ ID NO: 406, a VL CDR1 comprising the amino acid sequence shown in SEQ ID NO: 441, a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 436, and a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 439;
(c) a VH CDR1 comprising the amino acid sequence shown in SEQ ID NO: 415, a VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 417, a VH CDR3 comprising the amino acid sequence shown in SEQ ID NO: 335, a VL CDR1 comprising the amino acid sequence shown in SEQ ID NO: 430, a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 341, and a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 342;
(d) a VH CDR1 comprising the amino acid sequence shown in SEQ ID NO: 332, a VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 417, a VH CDR3 comprising the amino acid sequence shown in SEQ ID NO: 335, a VL CDR1 comprising the amino acid sequence shown in SEQ ID NO: 430, a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 341, and a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 446;
(e) a VH CDR1 comprising the amino acid sequence shown in SEQ ID NO: 419, a VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 421, a VH CDR3 comprising the amino acid sequence shown in SEQ ID NO: 423, a VL CDR1 comprising the amino acid sequence shown in SEQ ID NO: 431, a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 341, and a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 432;
(f) VH CDR1 comprising the amino acid sequence shown in SEQ ID NO: 425, a VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 427, a VH CDR3 comprising the amino acid sequence shown in SEQ ID NO: 429, a VL CDR1 comprising the amino acid sequence shown in SEQ ID NO: 431, a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 433, and a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 434;
(g) VH CDR1 comprising the amino acid sequence shown in SEQ ID NO: 447, a VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 449, a VH CDR3 comprising the amino acid sequence shown in SEQ ID NO: 451, a VL CDR1 comprising the amino acid sequence shown in SEQ ID NO: 431, a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 452, and a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 453;
(h) VH CDR1 comprising the amino acid sequence shown in SEQ ID NO: 402, a VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 404, a VH CDR3 comprising the amino acid sequence shown in SEQ ID NO: 406, a VL CDR1 comprising the amino acid sequence shown in SEQ ID NO: 435, a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 436, and a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 437;
(i) VH CDR1 comprising the amino acid sequence shown in SEQ ID NO: 402, a VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 404, a VH CDR3 comprising the amino acid sequence shown in SEQ ID NO: 406, a VL CDR1 comprising the amino acid sequence shown in SEQ ID NO: 435, a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 436, and a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 438;
(j) VH CDR1 comprising the amino acid sequence shown in SEQ ID NO: 407, a VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 404, a VH CDR3 comprising the amino acid sequence shown in SEQ ID NO: 406, a VL CDR1 comprising the amino acid sequence shown in SEQ ID NO: 435, a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 436, and a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 437;
(k) VH CDR1 comprising the amino acid sequence shown in SEQ ID NO: 407, a VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 404, a VH CDR3 comprising the amino acid sequence shown in SEQ ID NO: 406, a VL CDR1 comprising the amino acid sequence shown in SEQ ID NO: 435, a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 436, and a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 439;
(l) VH CDR1 comprising the amino acid sequence shown in SEQ ID NO: 407, a VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 404, a VH CDR3 comprising the amino acid sequence shown in SEQ ID NO: 406, a VL CDR1 comprising the amino acid sequence shown in SEQ ID NO: 440, a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 436, and a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 439;
(m) VH CDR1 comprising the amino acid sequence shown in SEQ ID NO: 407, a VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 404, a VH CDR3 comprising the amino acid sequence shown in SEQ ID NO: 406, a VL CDR1 comprising the amino acid sequence shown in SEQ ID NO: 441, a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 436, and a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 439;
(n) VH CDR1 comprising the amino acid sequence shown in SEQ ID NO: 402, a VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 404, a VH CDR3 comprising the amino acid sequence shown in SEQ ID NO: 406, a VL CDR1 comprising the amino acid sequence shown in SEQ ID NO: 435, a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 436, and a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 439; or
(o) VH CDR1 comprising the amino acid sequence shown in SEQ ID NO: 407, a VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 409, a VH CDR3 comprising the amino acid sequence shown in SEQ ID NO: 406, a VL CDR1 comprising the amino acid sequence shown in SEQ ID NO: 441, a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 436, and a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 439.